Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

65.68
+0.17000.26%
Post-market: 65.800.1200+0.18%19:30 EDT
Volume:1.60M
Turnover:105.26M
Market Cap:12.69B
PE:173.31
High:66.05
Open:65.96
Low:65.29
Close:65.51
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:0.85
T/O Rate:0.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:2.01
PE(LYR):36.49

Loading ...

Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT) and BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Aug 17

U.S. Research Roundup- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies

Reuters
·
Aug 17

Biomarin Pharmaceutical Inc. : Piper Sandler Raises Target Price to $88 from $82

THOMSON REUTERS
·
Aug 17

BioMarin (BMRN) Is Up 5.6% After Raising 2026 Revenue Outlook and Filing ESOP Shelf Registration

Simply Wall St.
·
Aug 17

BioMarin to Present at Canaccord Genuity Annual Growth Conference

Reuters
·
Aug 10

Analysts Conflicted on These Healthcare Names: Evolent Health (EVH), Eli Lilly & Co (LLY) and BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Aug 10

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 08

BioMarin price target raised to $86 from $80 at BofA

TIPRANKS
·
Aug 07

BioMarin Lifts 2026 Outlook on Strong Voxzogo Sales, Wedbush Says

MT Newswires Live
·
Aug 07

BioMarin price target raised to $124 from $119 at Morgan Stanley

TIPRANKS
·
Aug 07

Biomarin Pharmaceutical : Oppenheimer Raises Target Price to $97 from $95

THOMSON REUTERS
·
Aug 07

BioMarin Pharmaceutical Price Target Raised to $60.00/Share from $50.00 by HC Wainwright & Co.

Dow Jones
·
Aug 07

Morgan Stanley Adjusts PT on BioMarin Pharmaceutical to $124 From $119, Maintains Overweight Rating

MT Newswires Live
·
Aug 07

Analysts Have Conflicting Sentiments on These Healthcare Companies: Genmab (GMAB), Cytokinetics (CYTK) and BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Aug 07

BioMarin Pharmaceutical (BMRN) Could Be 30% Below Fair Value On Raised Guidance

Simply Wall St.
·
Aug 07

BioMarin Pharmaceutical Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 07

GUIDANCE: (BMRN) BioMarin Pharmaceutical Expects Full Year 2026 Adjusted EPS Range $4.90 - $5.10, vs. FactSet Est of $4.94

MT Newswires Live
·
Aug 07

BioMarin Q2 GAAP Net Income Drops 81% to $45 Million; Revenue Rises 20% to $990 Million

Reuters
·
Aug 07

BioMarin Q2 Revenue Beats Estimates; Raises 2026 Outlook

Reuters
·
Aug 07

Biomarin Pharmaceutical Q2 Adj. EPS $1.20 Beats $0.69 Estimate, Sales $990.000M Beat $926.908M Estimate

Benzinga Earnings
·
Aug 07